Lipitor reduces cardiovascular risk in diabetes

The licensed indications for Lipitor (atorvastatin) have been extended allowing the statin to be used for the prevention of cardiovascular disease in patients with diabetes who have at least one additional risk factor.

The statin may be used in such patients irrespective of whether their cholesterol levels are raised and even though coronary heart disease is not clinically evident.

The extension to Lipitor's licence follows the results of a major trial involving almost 3,000 patients with type II diabetes, without a prior history of cardiovascular disease and with LDL cholesterol less than 4.14 mmol/L, who had at least one of the following risk factors: hypertension, smoker, retinopathy, microalbuminuria or macroalbuminuria. After 3.9 years on a dose of 10 mg daily, Lipitor significantly reduced the risk of fatal and non-fatal major cardiovascular events such as stroke and myocardial infarction.

Further information: Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Tel: (01304) 616161.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases